ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)
| Status: | Recruiting |
|---|---|
| Conditions: | Shingles, Shingles, Infectious Disease |
| Therapuetic Areas: | Dermatology / Plastic Surgery, Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 50 - Any |
| Updated: | 8/12/2016 |
| Start Date: | May 2012 |
| End Date: | October 2023 |
| Contact: | Toll Free Number |
| Phone: | 1-888-577-8839 |
Post-Licensure Observational Study of the Long-term Effectiveness of ZOSTAVAX™
This study will describe the impact of vaccination with ZOSTAVAX™ on the epidemiology of
herpes zoster (HZ) in a cohort of vaccinated participants 50 years or age or older, compared
to a cohort of unvaccinated participants.
herpes zoster (HZ) in a cohort of vaccinated participants 50 years or age or older, compared
to a cohort of unvaccinated participants.
Inclusion Criteria:
- Participants with continuous Kaiser Permanente Northern California (KPNC) membership
since becoming age-eligible for ZOSTAVAX™ and with 12 months of continuous enrollment
in KPNC before their study start date
Exclusion Criteria:
We found this trial at
1
site
Click here to add this to my saved trials
